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Abstract
Sialoglycoconjugate contents of several milk replacers (MR) currently used in Spain have been determined. The ingestion of
these compounds by calves fed bovine milk or MR is also discussed. Total sialic acids and glycoprotein-, oligosaccharide-,
casein-, and lipid-bound sialic acids and free sialic acid were determined. High sialic acid contents in all the fractions studied,
including total sialic acids, were found. N-acetylneuraminic acid was found to be the major sialic acid in MR. However, MR-D
and H had a high N-glycolylneuraminic acid (NeuGc) content in all fractions (15-40%), while E and F only had a high NeuGc
content in the glycoprotein fraction. Five different sialyloligosaccharides -3’-sialyllactose, 6’-sialyllactose, 3’-sialyllactosamine,
6’-sialyllactosamine, and disialyllactose, which are the most abundant oligosaccharides in bovine milk- were detected in theMR.
Samples B to I contained high amounts of these oligosaccharides. The content of individual gangliosides was very similar to that
of bovine milk, with GD3 as the major ganglioside. Although MR are not formulated as regards their sialic acid content, high
amounts of sialic acid-containing glycoconjugates with high levels of NeuGc, a sialic acid critical in the adhesion of some
Escherichia coli strains to calf intestinal epitheliumwere detected.The ingestion ofMR analyzed in this work could protect new-
born calves from several enteric pathogens.
Additional key words: gangliosides, milk oligosaccharides, sialic acids.
Resumen
Contenido de sialoglicoconjugados de algunos lactorreemplazantes usados en la alimentación de terneros recién nacidos
En este trabajo se analizó el contenido de sialoglicoconjugados de diferentes lactorreemplazantes (MR) usados habitualmen-
te en España. Además, se ha comparado la ingesta de estos compuestos por terneros alimentados con leche materna o MR. Se
determinó el contenido de ácidos siálicos totales, ácidos siálicos libres y ácidos siálicos unidos a glicoproteínas, a oligosacári-
dos y a caseína, habiéndose encontrado una elevada cantidad de los mismos en todas las fracciones estudiadas. El ácido N-ace-
tilneuramínico es el ácido siálico mayoritario de todos losMR. Sin embargo, losMR-D yH tienen un elevado contenido de ácido
N-glicolilneuramínico (NeuGc) en todas las fracciones estudiadas (15-40%). Por el contrario, los MR-E y F sólo tienen grandes
cantidades de NeuGc en la fracción de glicoproteínas. En cuanto al contenido de oligosacáridos sialilados, se encontraron cinco
diferentes (3’-sialillactosa, 6’-sialillactosa, 3’-sialillactosamina, 6’-sialillactosamina y disialillactosa), que son a su vez los oligo-
sacáridos sialilados más abundantes de la leche bovina. La distribución de los gangliósidos individuales que se ha encontrado es
muy similar a la de la leche bovina, siendo GD3 el gangliósido más abundante. Aunque los MR no han sido formulados tenien-
do en cuenta su contenido de ácidos siálicos, se encontraron en ellos grandes cantidades de sialoglicoconjugados con una eleva-
da proporción de NeuGc, un ácido siálico muy importante en la adhesión de algunas cepas de Escherichia coli al epitelio intes-
tinal de los terneros. La ingestión de los MR analizados en este estudio podría proteger a los terneros recién nacidos frente a
patógenos entéricos.
Palabras clave adicionales: ácidos siálicos, gangliósidos, oligosacáridos de la leche.
Abbreviations used: CBSA (casein-bound sialic acid), FSA (free sialic acid), GBSA (glycoprotein-bound sialic acid), HPLC (high-per-
formance liquid chromatography), HPTLC (high-performance thin-layer chromatography), LBSA (lipid-bound sialic acid), mAb (mono-
clonal antibodies), MR (milk replacer), NeuAc (N-acetylneuraminic acid), NeuGc (N-glycolylneuraminic acid), SD (standard deviation),
TLC (thin-layer chromatography), TSA (total sialic acids).
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Introduction
The composition of milk is specifically adapted to
provide the essential nutritional and immunological ele-
ments required by the newborn. Sometimes, newborns
may circumstantially be fed with milk formulas or
replacers when breastfeeding is not possible. Since
bovine milk has become an important food for humans,
dairy farms are forced to use MR for feeding neonatal
calves. MR are designed with regard to major compo-
nents, such as proteins, lipids, and carbohydrates, which
must be manufactured from different sources in order to
obtain more economic products (Heinrichs et al., 1995).
However, little or no attention has been paid to other
minor components such as hormones, vitamins, growth
factors or glycoconjugates. Glycoconjugates have been
proposed to play an important role in the defense of
newborns against infection, acting as putative receptors
for certain bacteria, and thereby blocking their patho-
genic effects in the small intestine (Newburg, 1999).
Antibiotics have been extensively used in MR with
much success against infectious diseases, but some con-
cern has arisen about the risk of antibiotic resistance
and the presence of such compounds in food intended
for human consumption. For this reason, several prebi-
otic products have been tested as alternative anti-infec-
tives, such as different oligosaccharides (Quigley et al.,
1997, 2002; Heinrichs et al., 2003) and serum glycopro-
teins (Morril et al., 1995; Nollet et al., 1999; Quigley et
al., 2002). The use of probiotic bacterial has also been
described (von Buenau et al., 2005)
Due to the very extensive practice of the use of MR
feeding in calves, it seems that knowledge of the sialo-
glycoconjugate composition of these products is of con-
siderable value, in view of the recognized protective role
of these compounds. This paper describes the sialoglyco-
conjugate composition of several MR that are currently
used in Spain and compares sialoglycoconjugate inges-




and 6’-sialyllactosamine were purchased from Glyko
(Upper Heyford, UK). Disialyllactose was purchased
from Sigma (St. Louis, Mo, USA).
Sephadex G-50, DEAE-Sephadex A-25, Dowex 2x8,
orcinol, resorcinol, ninhydrin, N-acetylneuraminic acid
(NeuAc) and N-glycolylneuraminic acid (NeuGc) were
from Sigma (St. Louis, Mo, USA) and the sulfophos-
phovanillin test, thin-layer chromatography (TLC) and
high-performance thin-layer chromatography (HPTLC)
plates, n-hexane and acetonitrile were from Merck
(Darmstadt, Germany).
Monoclonal antibodies (mAb) P3, 14F7 and R24
were a kind gift from the Centro de Inmunología Mole-
cular (Havana, Cuba). Anti-A2B5 [mouse immunoglubu-
lin M (IgM) was provided by Roche Molecular Biochem-
icals (Manheim, Germany). Anti-9-0-acetyl-GD3 (clone
JONES, mouse IgG), mouse polyvalent IgG-, IgM- IgA-
biotin conjugated, ExtrAvidin-alkaline phosphatase, and
FAST BCIP/NBT (5-bromo-4-chloro-3-indolyl phos-
phate /nitro blue tetrazolium were from Sigma (St. Louis,
MO, USA). Poly isobutyl methacrylate (PIBM) was from
Aldrich Chemical Company (Milwaukee, WI, USA).
Albumin from bovine serum (BSA) was provided by
Fluka (Buchs, Switzerland).
Milk replacers
Nine MR that are currently used in Spain from three
different companies were analysed. MR-A is a
colostrum replacer and all others are MR to be adminis-
tered to calves after colostrum consumption.
Analitycal procedures
MRwere reconstituted in distilled water (0.1 g mL-1).
Total lipids were determined by the sulfophospho-
vanillin Merkotest. Proteins and total carbohydrates
were determined by a modification of the Lowry proce-
dure as described by Markwell et al. (1978) and by the
phenol sulphuric acid assay as described by Dubois et
al. (1956), respectively.
Sialoglycoconjugate fractions (oligosaccharides, gly-
coproteins and casein) were obtained from skimmed
samples (defatted by centrifugation at 3,000xg, 30 min
at 4ºC and filtered through glass wool) as described in a
previous paper (Martín et al., 2001a). Analyses of the
total sialic acid content (TSA) of MR and that of the
fractions were also carried out as described (Martín et
al., 2001a). Free sialic acids (FSA) were determined by
the thiobarbituric acid procedure in the oligosaccharide
fraction after purification by ion-exchange chromato-
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(acetate form) column (30 x 1.5 cm; 25 mL bead volume)
after purification on Sephadex G-25. The column was
equilibrated with 1 mM pyridine acetate, pH 5.2, and the
sample was applied in the same solvent. Neutral oligosac-
charides were eluted with 250 mL of 1 mM pyridine
acetate. Sialyloligosaccharides were eluted with 100 mM
pyridine acetate. Fractions were evaporated to dryness,
taken up in distilled water and lyophilized.
Sialylated oligosaccharide contents were analyzed by
high performance liquid chromatography (HPLC)
according to the method previously described by
Michalski (1995). Analyses were performed on aWaters
apparatus (Waters, Milford, MA), using a NH2-bound
silica column (Carbohydrate Analysis, 300 x 3.9 mm,
Waters). HPLC elution of samples was performed using
a gradient of acetonitrile and 15 mM KH2PO4 adjusted
to pH 5.2; isocratic elution with 25% 15 mM KH2PO4
for 10 min, linear gradient up to 50% 15 mM KH2PO4
for 50 min, maintaining these conditions for 15 min.
Flow rate was 1 mL min-1. Oligosaccharides were
detected at 206 nm and identified by comparison of
their retention times with those of standard oligosaccha-
rides injected previously. Sometimes, individual stan-
dards were injected together with the sample and the
resulting chromatographic profile was compared with
the native sample profile. Oligosaccharide quantifica-
tion was carried out from the calibration curves of stan-
dard oligosaccharides using Millenium software
(Waters) coupled to the HPLC system. All assays were
carried out in triplicate.
Several sialyloligosaccharide standards from human
milk and bovine colostrum of known concentration
were injected to obtain calibration curves on the HPLC
apparatus.
Sialyloligosaccharides were also separated by
HPTLC on silicagel 60 plates using butanol/ ethanol/
water/ acetic acid/ pyridine 5:50:15:1.5:5 by vol.
Results
Tables 1 and 2 show respectively the general composi-
tion (protein, lipids and carbohydrates) and the glycocon-
jugate-bound sialic acid distribution [TSA, glycoprotein-
bound-sialic acids (GBSA), oligosaccharide-bound sialic
acids (OBSA), FSA, casein-bound sialic acids (CBSA)
and LBSA] of the different MR.
Glycoprotein-bound sialic acid (Table 2) varied from
256.9 to 615.5 µg g-1. MR-A had the highest content,
probably due to its high protein content, including con-
graphy on Dowex 2x8 (Aminoff, 1961). Identification
of sialic acid types was performed on silica gel 60
HPTLC plates using propanol/ 0.57 M aqueous ammo-
nia, 7:3 by vol., as solvent. They were visualized with
resorcinol reagent (Svennerholm, 1957). The relative
amount of each sialic acid was determined by scanning
densitometry (Puente and Hueso, 1993).
Extraction of gangliosides
Gangliosides were prepared according to Puente et
al. (1992) and quantified as lipid-bound sialic acid
(LBSA) by the resorcinol procedure (Svennerholm,
1957). They were also separated on silica gel 60 HPTLC
plates using the following solvent system: chloro-
form/methanol/water (50:45:10, by vol.) containing
0.02% CaCl2. Individual gangliosides (ganglioside pat-
tern) were analysed in a dual-wavelength densitometer
(Shimadzu CS 9000, Kyoto, Japan) after separation by
HPTLC and development with resorcinol reagent.
Immunostaining on silica gel 60 HPTLC plates to iden-
tify individual gangliosides was performed as previous-
ly reported (Martín et al., 2001b). Different mAb
against gangliosides were used.
Determination of the sialyloligosaccharide
content
Isolation of total oligosaccharides was performed as
described by Kobata (1972), with several modifications.
Briefly, samples (2 g in 20 mL of distilled water) were
defatted by centrifugation (3,000xg, 30 min, 4ºC) and
filtered through glass wool. The filtrates were mixed
with two volumes of ethanol and allowed to stand
overnight at 4ºC. Most proteins and lactose precipitated
and were removed by centrifugation at 0ºC. Ethanol was
eliminated by rotary evaporation.
A sialyloligosaccharide fraction was prepared
according to Parkinnen and Finne (1987) with several
modifications. The crude oligosaccharide fraction was
first purified by molecular exclusion chromatography
on a Sephadex G-25 column to eliminate residual pro-
teins and peptides. Ninhydrin (0.3 g ninhydrin in 95 mL
butanol) -positive fractions were discarded. Orcinol
(0.1% orcinol in 20% H2SO4) -positive fractions were
collected together and kept at –20ºC until use.
Sialyloligosaccharides were separated by ion-
exchange chromatography on a DEAE-Sephadex A-25
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siderable amounts of immunoglobulins that contain sia-
lic acids.
Oligosaccharide-bound sialic acid (Table 2) varied
from 851 to 5,154 µg g-1, MR-A having the highest con-
tent. This oligosaccharide fraction probably includes the
κ-caseinoglycomacropeptide insoluble in 12%TCA and
present in the whey derivatives from cheese manufac-
turing when this ingredient was used.
The CBSA content (Table 2) was also determined.MR-
E, F and I formulated as “zero type” (without casein), had
a very low (5 to 6%) CBSA content. Since those MR do
not have casein, the sialic acids found in this fraction pro-
bably belong to contaminating proteins other than casein
precipitated at pH 4.6. MR-A also had the highest content.
It has been also detected a high content of FSA.
The sialic acid types present in the different fractions
were also determined. NeuAc and NeuGc were detected
in all fractions (Table 3). MR-D and H had a high
NeuGc content in all fractions (15-40%). MR-E and F
only had a high NeuGc content in the glycoprotein frac-
tion. MR-C and D from the same commercial supplier
had a very similar composition in all fractions. Howe-
ver, samples E and F, also from the same commercial
supplier, had large differences in their TSA, GBSA and
OBSA contents, even though the ingredients used by the
supplier to formulate both MR were also very similar.
Five different sialyloligosaccharides -3’-sialyllactose,
6’-sialyllactose, 3’-sialyllactosamine, 6’-sialyllac-
tosamine and disialyllactose- were detected in the MR
(Table 4). MR-A had a very low content in these
oligosaccharides (254.6 µg g-1); however, MR-B to I con-
tained between 680 and 1,666 µg g-1. The content of indi-
vidual oligosaccharides was very similar among the MR
belonging to the same supplier, -C and D, E and F, H and
I but different from that of others. In general, the samples
had high levels of 3’-sialyllactose and 6’-sialyllactose,
the two sialylated oligosaccharides most abundant in
bovine milk. 3’-sialyllactose predominated in MR-B and
D, and 6’-sialyllactose in E, F and I. MR-G had the hig-
hest content (1,666 µg g-1) and a different composition,
with a very high content in 3’-sialyllactose, followed by
an unusually high content in 6’-sialyllactosamine.
Finally, the individual ganglioside distribution of MR
has also been determined (Table 5). Seven different gan-
gliosides designated G1 to G7 according to their mobili-
ty (increasing polarity) were detected by HPTLC. They
were identified by co-migration with authentic standards
and analyzed by the HPTLC-overlay method using spe-
cific mAb (for ganglioside nomenclature see Martín et
al., 2003). Ganglioside G1 co-migrated with standard
NeuAc-GM3 and reacted with mAb 14F7 (specific for
NeuGc-containing GM3). The data suggest that G1 could
be a mixture of NeuGc- and NeuAc-containing GM3. G2
reacted with the Jones anti-O-acetyl GD3 mAb. G2 was
identified as O-acetyl GD3. G3 showed a mobility pat-
tern identical to that of GD3 and reacted strongly with
Milk replacer Protein Lipids Carbohydrates
A 829.4±15.9 108.1±4.4 79.1±4.6
B 220.7±2.0 190.8±4.4 493.7±27.9
C 254.9±5.2 165.8±7.2 367.8±5.6
D 228.4±1.5 148.8±4.7 422.3±9.7
E 302.3±1.5 205.8±3.8 517.7±9.8
F 206.5±3.1 206.8±6.9 409.1±37.0
G 190.3±11.7 201.2±20.5 461.0±13.7
H 178.7±15.1 210.0±30.4 497.1±24.8
I 169.1±17.8 242.2±1.9 493.1±27.4
Table 1. General composition of the different milk replacers
(mg g-1 dry weight milk replacer)
Date are means ± SD of three different experiments
a TSA, total sialic acids. b GBSA, glycoprotein-bound sialic acids. c OBSA, oligosaccharide-bound sialic acids. d FSA, free sialic acids.
e CBSA, casein-bound sialic acids. f LBSA, lipid-bound sialic acid. Data are means ± SD of three different experiments. g ND, not determined
Milk replacer TSAa GBSAb OBSAc FSAd CBSAe LBSAf
A 13,593.3±1251.4 6,151.5±86.0 5,154.3±107.5 2,038.9±160.6 1,045.1±35.0 41.4±2.2
B 3,395.7±176.9 1,108.8±18.8 1,640.9±85.9 510.7±17.5 300.5±8.7 38.2±2.5
C 1,498.7±58.9 595.6±30.0 621.1±17.9 230.8±9.5 306.0±15.1 5.1±0.2
D 1,512.0±91.0 511.0±16.5 777.0±21.8 205.6±12.4 383.3±7.6 5.3±0.4
E 5,198.3±348.8 659.6±26.1 3,504.5±94.9 675.8±45.3 22.8±7.3 15.1±1.9
F 2,458.3±110.8 335.8±28.5 1,541.7±37.7 356.4±17.2 16.9±1.3 18.5±1.5
G 3,465.4±102.7 654.5±30.7 2,126.2±48.1 537.1±17.9 32.4±1.8 3.7±0.0
H 1,970.8±114.4 621.0±32.3 923.0±31.4 315.3±13.7 379.7±3.1 4.1±0.0
I 2,119.4±25.6 256.9±15.1 1,273.1±95.4 349.7±20.6 15.5±1.9 NDg
Table 2. Glycoconjugate-bound sialic acid distribution of the different milk replacers (mg g-1 dry weight milk replacer)
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R24, a mAb with a high degree of specificity against
GD3. It was assumed to be GD3. Additionally, G3
showed a positive reaction with mAb P3, which is speci-
fic for NeuGc-containing gangliosides.Analysis suggests
the presence of NeuGc- and NeuAc-containing GD3. G4
reacted with Jones mAb and A2B5 (specific for GT3 as
well as for O-acetyl GT3) and was assumed to be O-
acetyl GT3. G6 was located in the trisialoganglioside
region and also reacted with the anti-A2B5 mAb and was
identified as GT3. G5 and G7 were not identified. In pre-
vious works (Takamizawa et al., 1986; Martín et al.,
2001b), they were tentatively designated on the basis of
their mobility on HPTLC plates as a monosialo- and a
trisialoganglioside sharing the same branched oligosac-
charide chain. G3 (GD3) is the most abundant ganglio-
side, accounting for 45 to 79% of the total lipid-bound
sialic acid content, followed by G6 (GT3). However, G1
(GM3) was not found, or only in trace amounts. The gan-
glioside profile of the samples suggests that bovine milk
fat, but no ovine or caprine milk fat, was used in the for-
mulation of the MR.
Discussion
MR are formulated to provide neonatal calves with a
sufficient carbohydrate, protein and lipid content to sup-
port animal growth and health. In the past, they were
mainly based on milk ingredients but the high prices of
milk products are now leading to the use of other animal
and vegetable sources to replace the most expensive
components, mainly proteins. These include spray-dried
animal plasma proteins, by-products of cheese manu-
facture, protein concentrates of oleaginous seeds, and
blended dry fat (edible lard, tallow and grease and
coconut and palm oils).
The values for protein, lipids and carbohydrates are
very similar to those indicated by the suppliers with
minor differences, probably due to the methodology
used in the determinations. Proteins, carbohydrates and
lipids are also in the range recommended for MR
(BAMN, 1997), except for the MR-A, with a very high
protein content, also probably due to its particular
design: a colostrum substitute that includes a high
amount of immunoglobulins. However, the carbohy-
drate (7.9%) and lipid (10.8%) contents seem to be low.
Considering a colostrum intake of 3 L in the first feed-
ing, a calf fed with MR-A would have a protein and
lipid intake 20% and three-fold lower, respectively, and
a carbohydrate intake three-fold higher than a calf fed
maternal colostrum. In fact, MR-A is probably a
colostrum supplement for use when the quantity or the
quality of maternal colostrum is not adequate rather
than a colostrum substitute. Nutrient ingestion was cal-
a TSA, GBSA, OBSA, CBSA and LBSA, see Table 2. b ND, not determined. Data are means of two different experiments
a 3’-sialyllactosamine; b ND, not detectable; c 3’-sialyllactose; d 6’-sialyllactosamine; e 6’-sialyllactose; f disialyllactose.
A B C D E F G H I
TSAa 3.3 11.2 11.4 34.5 8.4 12.9 17.5 20.6 18.4
GBSA 12.0 11.4 10.3 24.9 19.8 25.3 19.4 14.8 23.1
OBSA 2.4 3.3 11.3 40.0 6.2 10.9 15.6 20.9 20.4
CBSA 14.3 23.6 11.3 19.4 NDb ND ND 11.9 ND
LBSA 12.2 traces traces traces traces traces 17.2 17.1 18.6
Table 3. NeuGc content of the different sialoglycoconjugate fractions of milk replacers. NeuGc content is expressed as percen-
tage of the total sialic acid content (NeuAc + NeuGc) of the samples
Sialyl
A B C D E F G H I
oligosaccharide
3’ SLNa 45.2±3.6 84.7±3.7 NDb 80.6±3.7 73.4±4.7 84.5±4.2 62.2±2.1 65.5±3.7 167.2±12.5
3’ SLc 84.7±5.0 455.5±19.0 282.2±10.5 493.5±16.7 168.3±2.1 269.3±8.9 861.9±39.7 274.6±10.5 271.8±7.8
6’ SLNd ND 39.7±1.2 13.6±1.6 16.0±2.4 60.7±7.4 41.9±2.5 434.2±16.8 41.2±0.8 11.6±1.0
6’ SLe 48.2±5.6 249.8±8.2 371.6±7.4 440.9±8.9 591.4±8.4 699.7±5.2 88.9±3.0 275.1±12.0 439.6±15.8
DSLf 76.5±3.0 191.0±6.8 13.0±2.3 59.6±0.9 343.6±7.9 313.3±9.6 218.8±12.8 67.8±4.9 145.7±4.8
Table 4. Content of the five most abundant sialyl oligosaccharides found in milk replacers (µg g-1 dry weight milk replacer). Data
are means ± SD of three different experiments
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culated taking into consideration the MR feeding proto-
col recommended by the commercial suppliers and the
recommendations of the Bovine Alliance Management
Nutrition (3 L of colostrum in the first feeding, 4 L d-1
of milk in the first and second weeks of life and 3-4 L
d-1 of milk in the third week) (BAMN, 1997). MR-B to
I provide calves with more proteins (20 to 25%) and car-
bohydrates (40%) and a lower amount of lipids (15%)
than the ingestion of mature milk.
However, MR are not formulated with regard to their
sialic acid content. In this sense, it could be surmised
that sialic acid intake by calves could be lower than in
those fed maternal colostrum or milk. Surprisingly, the
TSA content of the MR was high (1.5 to 13.5 mg g-1
MR), with the highest value for MR-A.When a calf was
fed with MR-A it received five-fold more sialic acid
than a calf fed maternal colostrum. When calves were
fed MR-B to I after colostrum ingestion in the 1st week
after birth, they received similar or slightly more sialic
acids than calves fed maternal milk. The differential
intake increased in the 2nd and 3rd weeks after birth,
being five-fold higher in the latter.
The MR had more OBSA than GBSA, in contrast
with bovine milk which has more GBSA than OBSA
(Martín et al., 2001a). FSA are abundant in bovine
(16% of TSA, Martín et al., 2001a) and ovine milk
(15%, unpublished data) and are also probably present
in derivatives from cheese manufacturing. Since bovine
milk has only low levels of NeuGc (5 to 10%), it seems
that those MR had been formulated using caprine or
ovine milk derivatives, which have been demonstrated
to contain high levels of NeuGc (unpublished data from
our group). This is also supported by the sialic acid
types found in the CBSA fraction. Since bovine casein
does not contain NeuGc, the samples seem to have been
formulated with ingredients containing ovine or caprine
casein, which contains large amounts of this sialic acid
(Alais and Jollès, 1961). It appears that the MR were
formulated with whey derivatives or lactoserum from
different animal sources (bovine, ovine, caprine) and at
variable ratios.
The MR analyzed in this work point to an elevated
sialic acid level in all the fractions studied, even though
they were not formulated with regard to their sialic acid
contents. However, the combination of the different
ingredients used to prepare MR results in sialoglyco-
conjugate levels exceeding the initial amount found in
mammalian milks. Whey-based raw materials are very
rich in all milk glycoconjugates and oligosaccharides
and increased use of such materials will result in high
contents of these micronutrients in MR. Furthermore,
since it has been proposed (Gustafsson et al., 2005) that
glycoproteins or glycolipids expressing multiple sets of
specific carbohydrate epitopes could be more protective
against pathogens than the same carbohydrate epitope
expressed in a single oligosaccharide, MR should pro-
bably be formulated to include high contents of GBSA
rather than of OBSA.
The biological significance of milk sialic acid-con-
taining glycoconjugates remains unclear. It has been
suggested that they could influence the functional
development of the neonatal intestine, the absorption of
nutrients, and the postnatal development of the intesti-
nal immune system (gut-associated lymphoid system,
GALT) and also that they could exert a defensive role,
acting as false soluble receptors for microorganisms and
microbial toxins (Dai et al., 2000).
The binding of several microorganisms (bacteria and
viruses) to different sialoglycoconjugates has been
described (Newburg, 1999; Dai et al., 2000). It has also
been demonstrated that milk glycoconjugates inhibit
bacterial adhesion to erythrocytes and other cellular sur-
Gangliosides were designated G1 to G7 according to their mobility on HPTLC plates. Mobility decrease from G1 to G7. Percentage of each
ganglioside (expressed as lipid-bound sialic acid) in the total lipid-bound sialic acid content. Data are means ± SD of three different experi-
ments. ND, not detectable
Gangliosides A B C D E F G H
G1 traces ND ND 2.5±0.8 4.0±0.1 ND traces traces
G2 4.5±0.4 3.5±0.5 3.4±0.8 6.5±0.2 2.7±0.1 2.8±0.2 4.1±0.1 6.2±0.1
G3 78.5±0.6 62.6±2.9 43.9±7.1 57.0±1.3 45.1±1.7 53.0±0.3 58.0±0.1 62.4±0.6
G4 ND 2.8±0.8 10.9±3.4 5.3±0.7 6.2±0.2 5.2±0.6 2.6±0.1 3.2±0.1
G5 4.3±0.4 2.1±0.3 5.0±0.3 ND 1.4±0.2 2.2±0.9 1.8±0.1 1.2±0.1
G6 10.1±1.1 23.3±1.1 31.7±1.4 26.6±0.5 31.3±1.5 24.3±1.3 33.7±0.1 27.0±0.6
G7 4.6±1.9 5.7±1.8 9.5±1.5 2.2±1.1 9.4±0.3 12.5±2.3 ND ND
Table 5. Distribution of individual gangliosides (ganglioside pattern) of milk replacers
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faces and that specific glycoconjugates inhibit specific
pathogens (Karlsson, 1998; Dai et al., 2000). NeuGc-
GM3 and other NeuGc-containing gangliosides have
been reported to be the main receptors for Escherichia
coli K99 adhesins in the intestinal epithelium of calves
(Teneberg et al., 1994). K99 is the most common fim-
bria expressed in enterotoxigenic E. coli strains isolated
from calves. Since MR have large amounts of NeuGc-
containing glycoconjugates, including gangliosides,
calves fed these MR could benefit from the protective
effect of these compounds against E. coli K99. Martín
et al. (2002 and 2003) reported the binding of bovine
milk gangliosides and sialyloligosaccharides to entero-
toxigenic E. coli strains isolated from calves. Bovine κ-
caseinoglycomacropeptide has been found to bind and
protect from Vibrio cholerae and E. coli enterotoxins; to
inhibit bacterial and viral adhesion to their hosts; to pro-
mote bifidobacterial growth, and to modulate the
immune system response (Brody, 2000). These benefi-
cial effects could be extrapolated to ovine or caprine κ-
caseinoglycomacropeptide, mainly taking into account
that they also have N-acetylgalactosamine, galactose
and NeuAc, but also high amounts of NeuGc (Alais and
Jollès, 1961). In this sense, a successful treatment of
experimental colibacillosis mediated by E. coli K99 and
F41 in calves with glycoprotein glycans from bovine
and porcine plasma has already been reported (Mouri-
cout et al., 1990; Nollet et al., 1999). The sialic acid
moiety, mainly NeuGc, seems to be critical in the
process. Thus the ingestion or administration of sialo-
glycoconjugates protect human and animals from infec-
tion by microorganisms, and indeed some of the above-
mentioned sialoglycoconjugates were found in the MR
studied here.
Even though the MR studied here were not formula-
ted as regards their micronutrient content but instead on
the basis of the content of fat, protein and carbohydrates
(macronutrients), a high glycoconjugate-bound sialic
acid content has been found in all fractions studied. This
means that calves fed these MR have sialic acid intakes
higher than those fed maternal milk or colostrum. Fur-
thermore, a high relative proportion of these sialic acids
is NeuGc, which has been described as the specific
receptor for E. coli K99, one of the most common
pathogens causing diarrhea in neonatal calves. The
ingestion of large amounts of NeuGc may be beneficial
for the healthy growth of calves.
MR also contain several sialyloligosaccharides,
namely 3’-sialyllactose, 6’-sialyllactose, 3’-sialyllac-
tosamine, 6’-sialyllactosamine and disialyllactose, pre-
viously reported in bovine milk that could also con-
tribute to active defense against pathogens, acting as
false receptors for microorganisms and their toxins.
In addition, the results might induce the dairy food
industries to formulate their milk replacers taking into
account not only the costs of ingredients but also their
sialoglycoconjugate content.
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